GLPwatch
Papers (12034)
Page 165 of 201, ranked by citation count.
- Super response to liraglutide in people with obesity: A case report and literature review.
- Glycemia shifts pancreatic islet rhythmicity by influencing interactions between δ cells and α cells.
- [Rare cause of insufficient metabolic control of diabetes mellitus - Case 10/2011].
- Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.
- Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.
- Adverse events associated with tirzepatide: a focus on subgroup-specific differences.
- Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.
- Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.
- Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
- Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.
- Liraglutide modulates adhesion molecules and enhances cell properties in three-dimensional cultures of olfactory ensheathing cells.
- Tirzepatide Tested for Type 2 Diabetes With High Cardiovascular Risk.
- A diabetic patient increased premature ventricular contractions after using liraglutide: a case report.
- Effect of liraglutide treatment on mitigation of hearing damage induced by multiday repeated high-intensity blasts.
- The Effect of Exenatide on Platelets Ratio Index and Fibrosis-4 Index in Obese Patients With Diabetes Mellitus.
- Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.
- The incretin system in the management of type 2 diabetes mellitus.
- The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
- [Benefits of telematic monitoring for weight loss in overweight and obese patients in times of confinement].
- Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis.
- Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
- Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
- [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
- Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
- Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.
- Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
- Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.
- Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews.
- Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
- Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes.
- Individual Variability in the Cardiometabolic Response to Tirzepatide: Moving Beyond the Average.
- Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.
- Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
- Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretion <i>in vitro</i> and <i>in vivo</i> of a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001.
- GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.
- Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
- Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature.
- Liraglutide (Saxenda) for weight loss.
- Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
- "Why you should (not) use semaglutide?": A critical discourse analysis on health professionals' videos of semaglutide for weight loss on Douyin.
- Perceptions and Attitudes Toward Oral Semaglutide Among Japanese Physicians and Individuals with Type 2 Diabetes: A Web-Based Survey.
- Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
- Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4.
- Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report.
- Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.
- Efficacy and safety of semaglutide in a diabetic and obese patient on incremental hemodialysis. Does it also contribute to preserving residual renal function?
- The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial.
- The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D.
- Recent diabetes issues affecting the primary care clinician.
- Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes.
- Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?
- Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.
- Granuloma annulare after starting semaglutide.
- Targeting cardiometabolic risk in type 1 diabetes through incretin physiology.
- The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.
- Semaglutide Hype or Hope: Evidence-based Review in Diabesity.
- Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview.
- Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.